Controversies in HIV Cure Research 18.3 0 Debate 1. Is there ongoing replication under HAART? Mario Stevenson and Frank Maldarelli Moderator: Steve Deeks.

Slides:

Advertisements

Similar presentations

Antiretroviral Drug Resistance

Advertisements

Antiretroviral Drug Resistance Anna Maria Geretti UCL Medical School & Royal Free Hampstead Medical School, London.

Effect of intensification of long-term highly active antiretroviral therapy (HAART) with raltegravir on proviral HIV-1 DNA in blood and gut associated.

Emerging patterns of drug resistance and viral tropism in cART-naïve and failing patients infected with HIV-1 subtype C Thumbi Ndung’u, BVM, PhD Associate.

New concepts in HIV: HIV immunopathogenesis, treatment and vaccine strategies - report back from pre-conference Nicolas Chomont VGTI-Florida.

Purging the HIV-1 Reservoir Through the Disruption of the PD-1 Pathway

HAART Highly Active Antiretroviral Therapy

Interactive Workshop “HIV Cure 101”: Challenges in identifying and targeting the HIV reservoir Sarah Palmer Centre for Virus Research Westmead Millennium.

Main questions on HIV persistence and on obstacles to HIV eradication Jean-Pierre Routy M.D. McGill University Montreal Toward an HIV cure: Insight into.

Offering ARV Treatment to All HIV-infected Persons in San Francisco Grant Colfax, MD Director of HIV Prevention and Research San Francisco Department of.

MODELING THE PROGRESSION AND TREATMENT OF HIV Presented by Dwain John, CS Department, Midwestern State University Steven M. Shechter Andrew J. Schaefer.

The role of HIV infection and Co-infections in Serious Non-AIDS Events Peter W. Hunt, M.D Associate Professor of Medicine, UCSF.

1 HIV Curative Strategies: Key Research Priorities Deeks S, et al., (2013) Nat Rev Immunol. 12(8):

Myeloid dendritic cells and HIV latency in resting T-cells Nitasha A Kumar, Vanessa A Evans, Suha Saleh, Candida de Fonseca Pereira, Paula Ellenberg, Paul.

Salvage Antiretroviral Therapy Guiding Principles, Strategies and the Role of Resistance Testing.

Over 50 million HIV/AIDS cases have occurred worldwide Over 40 million people are currently living with HIV/AIDS 95% of all cases are in developing countries.

Alternative RNA splicing in latently infected T cells generates chimeric cellular:HIV mRNAs with the potential to generate Tat and reactivate infection.

2014 “Towards an HIV Cure” symposium Melbourne A novel assay that precisely measures the size of the latent HIV reservoir reveals that ART-nai ̈ ve individuals.

Strategies for Targeting and Eradicating the HIV Reservoir

David M. Margolis, MD Professor of Medicine Towards an HIV cure: medical, social and ethical challenges in research and testing.

2014 “Towards an HIV Cure” symposium Melbourne The Immune Checkpoints PD-1, LAG-3 and TIGIT are Biomarkers of HIV Infected Cells During ART and Identify.

Blocviroc – an innovative treatment for HIV/AIDS Steve English Development Head, Antivirals.

Cell- and Tissue-based Measures of Viral Persistence Are Associated with Immune Activation and PD-1-Expressing CD4+ T cells H Hatano 1, V Jain 1, PW Hunt.

Estrogen blocks HIV re-emergence from latency and points to gender- specific differences in HIV reservoirs Jonathan Karn International AIDS Society Hammer.

Autologous T-cell therapy based on a lentiviral vector expressing long antisense RNA targeted against HIV-1 env gene influences HIV replication and evolution.

Factors associated with a low HIV reservoir in patients with prolonged suppressive antiretroviral therapy S. Fourati 1, R. Calin 2, G. Carcelain 3, P.

Myeloid cells matter Conclusions. Glut1+ CD14++ CD16+ Associated with inflammatory markers HIV Immune activation HIV-related diseases Joshua Anzigen:

Novel Approaches: Treatment and HIV Pathogenesis L. Trautmann, Ph.D. VGTI Florida.

HIV Cellular Pathogenesis III

Evaluation of residual HIV-1 replication among individuals receiving different antiretroviral treatment regimens Giron, LB; Tenore, S; Gabriel, R; Janini,

Studies of HIV Eradication: a Case for Using NHP Models Guido Silvestri, MD Yerkes National Primate Research Center Emory University School of Medicine.

Viral Tissue Reservoirs Are Determined Early and Little Viral RNA Is Detected during Suppression in the Macaque Model Zandrea Ambrose, Ph.D. Division of.

1 Modelling the interactions between HIV and the immune system in hmans R. Ouifki and D. Mbabazi 10/21/2015AIMS.

Anti-HIV Antibody Responses Reflect the Quantifiable HIV Reservoir Size Sulggi Lee, M.D., Ph.D. Assistant Professor of Medicine University of California,

Impact of Raltegravir on Immune Reconstitution and Thymopoiesis in HIV-1 Infected Patients with Undetectable Viremia Carolina Garrido, N Rallón, N Zahonero,

Effect of 24 Week Intensification with a CCR5-Antagonist on the Decay of the HIV-1 Latent Reservoir IAS HIV RESERVOIRS WORKSHOP, 16 & 17 JULY 2010, VIENNA.

Yerkes National Primate Research Center

Primary HIV-1 Infection Pathogenesis, Diagnosis, and Treatment Summary of Evidence Martin Markowitz M.D. Clinical Director and Staff Investigator Aaron.

Persistent HIV-1 infection in duodenal mucosa and memory CD8+ T cell differentiation Liliana Belmonte 1 PhD; Alberto Zalar 2 MD; Patricia Baré 1 PhD; Noel.

Are we most likely to cure HIV with gene therapy? Sharon R Lewin Director, Infectious Disease Unit, Alfred Hospital Professor, Department of Medicine,

Simplification from Protease Inhibitors to Once or Twice Daily Raltegravir: the ODIS trial Eugenia Vispo, Pablo Barreiro, Francisco Blanco, Sonia Rodríguez-Novoa*,

HIV Cellular Pathogenesis III Benhur Lee, M.D.. Adult v. infant (IgG v. IgA) CTL response (MHC tetramers) p24 antigenimia Ab response Viral load.

Learning About an HIV Cure by Doing Studies in HIV+ Subjects Alan Landay, PhD Professor and Chairman Department of Immunology/Microbiology Rush University.

HIV-1 infection decreases CD127 and PD1 expression on duodenal CD8+T cells Liliana Belmonte, PhD Academia Nacional de Medicina Buenos Aires, Argentina.

Sporadic excesses of unintegrated HIV DNA can occur in HIV+ patients on HAART Una O’Doherty University of Pennsylvania.

Persistent immune activation despite suppressive HAART is associated with higher risk for viral blips in HIV-1 infected individuals Alexander Zoufaly 1.

ImmunoPathogenesis of HIV Disease Overview of HIV Epidemic Basic biology of HIV-1 Stages of HIV Disease Viral and Cellular Dynamics after HAART HIV Therapy.

Title Box. “Towards an HIV Cure”: Presentation Outline -Why do we need a cure? -Is a cure feasible and what type of cure can we reach? -Why does HAART.

HBV (chronic) HIV ~400 million chronically infected

IAS Members Meeting July 19th 2011 Achievements and learning over the past 30 years: what do we need next? Françoise BARRÉ-SINOUSSI Regulation of Retroviral.

HIV: Science, Sex and Society. Lecture 1. Mechanisms of viral persistence in the face of antiviral therapy. Mario Stevenson, Ph.D Department of Medicine.

1 Adherence to ARV Therapy and Resistance HAIVN Havard Medical School AIDS Initiative in Vietnam.

The Future of HIV/AIDS: The Road to a Cure. How HIV persists during therapy?  Ongoing viral replication occurs in subjects on suppressive HAART (TW Chun,

Robert F. Siliciano, MD, PhD Professor of Medicine The Johns Hopkins University School of Medicine Baltimore, Maryland Update on HIV Cure Research FORMATTED:

Track A Orientation Guido Silvestri, M.D. Track A Co-Chair

Immune reconstitution Anjie Zhen, PhD

Beyond HAART What comes next?. Overview How far have we come in HIV since 1981?

2014 “Towards an HIV Cure” symposium Melbourne An Overview of HIV Cure Research in 2014 Diana Finzi, Ph.D. Director, Basic Science Program Division of.

Evolution and transmission in HIV Steve Paterson Review; Rambaut 2004 Nature Reviews Genetics 5: ‘The causes and consequences of HIV evolution’

HAART Initiation Within 2 Weeks of Seroconversion Associated With Virologic and Immunologic Benefits Slideset on: Hecht FM, Wang L, Collier A, et al. A.

Date of download: 7/6/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effect of Antiretroviral Therapy on Viral Load, CD4.

First-Line Treatment of HIV Infection With Either NNRTI- or PI-Based Regimens Effective for Long-term Disease Control Slideset on: MacArthur RD, Novak.

Barriers to HIV Cure Janet M. Siliciano, PhD

The impact of treatment duration on defective and expanded identical HIV genomes in T cell subsets from peripheral blood and tissues Eunok Lee.

State of HIV Cure Research

HIV Cure: Current Status and Future Perspectives

The block-and-lock approach

Engineering T Cells to Functionally Cure HIV-1 Infection

Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection Lin Shen, MD, Robert F. Siliciano,

Hematopoietic-Stem-Cell-Based Gene Therapy for HIV Disease

Presentation transcript:

Controversies in HIV Cure Research Debate 1. Is there ongoing replication under HAART? Mario Stevenson and Frank Maldarelli Moderator: Steve Deeks Debate 2. Will cell and animal models be informative in planning clinical trials for a cure (or will we only learn from doing the trials)? Alan Landay and Guido Silvestri Moderator: Rafick Sekaly Debate 3. How are we most likely to cure HIV? Gene Therapy vs Pharmacology Sharon Lewin and Keith Jerome Moderator: Mark Harrington Debate 1. Is there ongoing replication under HAART? Mario Stevenson and Frank Maldarelli Moderator: Steve Deeks Debate 2. Will cell and animal models be informative in planning clinical trials for a cure (or will we only learn from doing the trials)? Alan Landay and Guido Silvestri Moderator: Rafick Sekaly Debate 3. How are we most likely to cure HIV? Gene Therapy vs Pharmacology Sharon Lewin and Keith Jerome Moderator: Mark Harrington Mario Stevenson Ph.D University of Miami Miller School of Medicine. “There is ongoing replication under HAART”

A spirited debate!

What accounts for the extreme persistence of the viral reservoir? HAART stops all viral replication. Reservoir persistence is due to the intrinsic stability of the latently infected, resting CD4 T-cell. Residual replication continues due to incompletely suppressive HAART. Reservoirs are maintained by replenishment.

Viral surrogates in suppressive HAART? Sequence evolution Immune activation/inflammation Latently infected cell frequency Cell-associated viral RNA Residual viremia cDNA intermediates

Cytoplasm Nucleus ~10%

Cytoplasm Nucleus  Raltegravir  

Episomes increase upon Raltegravir intensification. Buzon et al., Nature Med. 2010

 Raltegravir   Therefore, an increase in episomes following Raltegravir intensification can only be explained by de novo infection. An increase in episomes requires: -infectious virions. -de novo viral synthesis of viral cDNA

The low level of replication may be insufficient for resistance development. A chronic virus source drives limited rounds of infection. If there is continued infection under HAART, why don’t we see development of resistance?

de novo infection: ongoing versus chronic infection.

Let’s ponder the issues and hopefully, come up with a rational game plan.

Years on completely suppressive HAART Infectious virus Intrinsic stability versus replenishment Time to eradication intrinsic stability replenishment 0

Monitoring the impact of treatment intensification: INTegRAL study by J. Picado, B. Clotet et al: impact of Raltegravir intensification. 69 patients on suppressive 3 drug HAART regimen randomized to intensify with Raltegravir (n=44) or to continue HAART (n=24). Episomal cDNA and immune activation parameters were monitored.